select a format

Single User License
USD 250 INR 16073
Site License
USD 500 INR 32145
Corporate User License
USD 750 INR 48218

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Tonix Pharmaceuticals Holding Corp (TNXP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Tonix Pharmaceuticals Holding Corp (TNXP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH272987D
  • |
  • Pages: 65
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Tonix Pharmaceuticals Holding Corp (Tonix), formerly Tamandare Explorations Inc. is a pharmaceutical company that offers drugs and medicines. The company develops pharmaceutical products and treatments for disorders of the central nervous system such as fibromyalgia, post traumatic stress disorder and episodic tension-type headache. Its products include TNX-102 SL and Tonmya. Tonix's TNX-102 SL product is a dose and formulation of cyclobenzaprine and is used for the treatment of fibromyalgia and post-traumatic stress disorder. Its tonmya is a formulation provided as cyclobenzaprine HCl sublingual tablets. It sells its products through a network of distributors across the US. Tonix is headquartered in New York, the US.

Tonix Pharmaceuticals Holding Corp (TNXP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Tonix Pharma Enters into Agreement with U.S. Army Medical Materiel Development Activity 11

Equity Offering 11

Tonix Pharmaceuticals Holding Raises USD8 Million in Public Offering of Shares 11

Tonix Pharma Raises USD5.2 Million in Public Offering of Units 13

Tonix Pharma Raises Funds in Private Placement of Shares 14

Tonix Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering of Shares for USD11.5 Million 15

Tonix Pharma Raises USD20.1 Million in Public Offering of Shares 17

Tonix Pharma Raises USD28.7 Million in Public Offering of Shares 18

Tonix Pharma to Raise USD8 Million in Private Placement of Shares 19

Tonix Pharma Completes Public Offering Of Shares For US$43.5 Million 21

Tonix Pharma Completes Public Offering Of Units For US$11.4 Million 22

Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$1 Million 24

Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$2.3 Million 26

Debt Offering 27

Tonix Pharmaceuticals Completes Private Placement Of Notes Due 2013 For US$1 Million 27

Acquisition 27

Tamandare Explorations Acquires TONIX Pharma 27

Tonix Pharmaceuticals Holding Corp-Key Competitors 29

Key Employees 30

Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Apr 17, 2017: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update 32

Nov 10, 2016: Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results 34

Aug 08, 2016: Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update 35

May 09, 2016: Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update 37

Mar 04, 2016: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update 39

Corporate Communications 41

Feb 25, 2016: Tonix Pharmaceuticals Appoints Chief Financial Officer 41

Jan 08, 2016: Tonix Pharmaceuticals Announces Management Change 42

Product News 43

11/02/2016: Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference 43

08/15/2016: Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Re 44

06/03/2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention 45

01/10/2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference 46

Product Approvals 47

Dec 19, 2016: Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA 47

Clinical Trials 48

Dec 08, 2016: Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder 48

Dec 02, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) 49

Nov 10, 2016: Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD 50

Nov 07, 2016: Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting 51

Nov 01, 2016: Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress 52

Oct 27, 2016: Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016 53

Sep 06, 2016: Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update 54

Aug 29, 2016: Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder 55

Jul 26, 2016: Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia 57

Jun 09, 2016: Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia 58

May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting 59

May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting 61

May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) 62

May 02, 2016: Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia 63

Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65

List of Figures

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Tonix Pharmaceuticals Holding Corp, Deals By Therapy Area, 2011 to YTD 2017 9

Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Tonix Pharma Enters into Agreement with U.S. Army Medical Materiel Development Activity 11

Tonix Pharmaceuticals Holding Raises USD8 Million in Public Offering of Shares 11

Tonix Pharma Raises USD5.2 Million in Public Offering of Units 13

Tonix Pharma Raises Funds in Private Placement of Shares 14

Tonix Pharma Completes Underwriter's Exercise of Over-Allotment Option of Public Offering of Shares for USD11.5 Million 15

Tonix Pharma Raises USD20.1 Million in Public Offering of Shares 17

Tonix Pharma Raises USD28.7 Million in Public Offering of Shares 18

Tonix Pharma to Raise USD8 Million in Private Placement of Shares 19

Tonix Pharma Completes Public Offering Of Shares For US$43.5 Million 21

Tonix Pharma Completes Public Offering Of Units For US$11.4 Million 22

Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$1 Million 24

Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$2.3 Million 26

Tonix Pharmaceuticals Completes Private Placement Of Notes Due 2013 For US$1 Million 27

Tamandare Explorations Acquires TONIX Pharma 27

Tonix Pharmaceuticals Holding Corp, Key Competitors 29

Tonix Pharmaceuticals Holding Corp, Key Employees 30

Tonix Pharmaceuticals Holding Corp, Other Locations 31

Tonix Pharmaceuticals Holding Corp, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Tonix Pharmaceuticals Holding Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com